Zoetis, Inc. Stock Hits New 52-Week Low at USD 113.29

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 113.29 as of March 27, 2026. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 36.62%, contrasting sharply with the S&P 500's gain of 11.87% during the same period. The company's market capitalization stands at USD 53,244 million, categorizing it as a large-cap entity. Zoetis maintains a price-to-earnings (P/E) ratio of 20.00, indicating its valuation relative to earnings. The stock also offers a dividend yield of 1.71%, appealing to income-focused investors. Despite the recent price drop, Zoetis has demonstrated strong management efficiency, highlighted by a return on equity (ROE) of 80.42%. The company has shown resilience with a robust operating cash flow of USD 2,929 million and a healthy debt-to-EBITDA ratio of 1.22 times, suggesting a strong capacity to manage its debt obligations. Overall, while the stock has faced challenges in the short term, Zoetis continues to exhibit solid financial metrics that underscore its operational strength within the industry.